Breakthrough Pill Extends Pancreatic Cancer Survival | Dover News

Dover News Today | 2 Min News | The Daily News Now! · Aug 27, 2026 · 1m

FDA just approved a breakthrough daily pill, Rasonque, for the most common type of pancreatic cancer—targeting a mutated protein that’s fueled treatment-resistant tumors for decades. In a landmark study, patients on this drug lived nearly twice as long compared to chemo, with fewer severe side effects. The approval came ahead of schedule, spurred by public demand—including former Senator Ben Sasse’s advocacy—and marks a major leap for a cancer long considered “undruggable.” This molecular glue technology could soon extend beyond pancreatic cancer, offering hope for other tough-to-treat…